Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/IB2009/053626external-prioritypatent/WO2010023594A1/en
Application filed by PfizerfiledCriticalPfizer
Publication of TN2011000066A1publicationCriticalpatent/TN2011000066A1/en
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Abstract
IL EST DECRIT DANS LE PRESENT MEMOIRE DES COMPOSES DE FORMULE(I) ET LEURS UTILISATIONS POUR LE TRAITEMENT DE MALADIES, D' AFFECTIONS ET DE TROUBLES A MEDIATION PAR DES INHIBITEURS DU TRANSPORTEUR SODUIM - GLUCOSE (EN PARTICULIER DES INHIBITEURS DE SGLT2) . LES COMPOSES DECRITS DANS LE PRESENT MEMOIRE SONT UTILES POUR LA PREVENTION ET LE TRAITEMENT DE L' OBESITE ET DE SES COMORBIDITES ASSOCIEES , EN PARTICULIER LE DIABETE DE TYPE II (TYPE2) .IT IS DESCRIBED IN THE PRESENT MEMORY OF THE COMPOUNDS OF FORMULA (I) AND THEIR USES FOR THE TREATMENT OF DISEASES, DISORDERS AND MEDIATION DISORDERS BY INHIBITORS OF THE SODUIM - GLUCOSE CARRIER (ESPECIALLY SGLT2 INHIBITORS). THE COMPOUNDS DESCRIBED IN THIS MEMORY ARE USEFUL FOR THE PREVENTION AND TREATMENT OF OBESITY AND ITS ASSOCIATED COMORBIDITIES, ESPECIALLY DIABETES TYPE II (TYPE2).
PHARMACEUTICAL COMPOSITION CONTAINING GLUCOPYRANOSYL DIPHENYLMETHANE DERIVATIVES, ITS GALENIC DOSAGE FORM, PREPARATION METHOD AND USES FOR ENHANCED GLYCEMIC REGULATION IN PATIENT